Abstract: A surgical instrument includes a shaft assembly, an end effector, a driving assembly, at least one motor, and a motor controller. The at least one motor is configured to actuate the driving assembly to deploy staples. The motor controller is in communication with the motor. The motor controller is configured to determine whether values of first and second trigger variables exceed predetermined thresholds. The motor controller is configured to modify at least one motor control parameter in response to determining that the values of the first and second trigger variables exceed the predetermined thresholds. The motor control parameters include a motion profile instituted by the motor controller for the motor, a waiting period during which power to the motor is reduced or stopped, or the predetermined threshold relating to current or force for proximal retraction to be different from the predetermined threshold relating to current or force for distal advancement.

Abstract: A surgical stapling instrument includes a shaft assembly, an end effector at a distal end of the shaft assembly and having a first jaw with an anvil and a second jaw operable to cooperate with the first jaw to clamp tissue, and a cartridge inserted into the second jaw. The cartridge includes staples, a movable member translatable distally during a firing stroke to discharge the staples into tissue, a first sensor assembly configured to monitor a first condition of the cartridge, and a second sensor assembly configured to monitor a second condition of the cartridge. A first processor is coupled with the first and second sensor assemblies and is configured to receive first and second signals from the sensor assemblies, respectively, where each signal is indicative of the respective condition of the cartridge. The first processor is configured to selectively permit or restrict the firing stroke based upon the signals.

Abstract: A surgical instrument is disclosed including an end effector configurable between an open state and a clamped state, a firing member movable from an unfired position toward a fired position during a firing stroke, a manually-driveable closure system, a motor-powered firing system, and a control system. The motor-powered firing system is configured to drive the firing member through the firing stroke. The control system is configured to detect, at a first time point, the end effector reaching the clamped state with the manually-driveable closure system, detect, at a second time point, the actuation of the motor-powered firing system, set a firing motion parameter of the motor-powered firing system based on an elapsed time from the first time point to the second time point, and drive the firing member through the firing stroke with the motor-powered firing system using the firing motion parameter.

Abstract: A surgical instrument system comprising a motor system and a control circuit is disclosed. The motor system comprises a motor and a drive train coupleable to the motor and configured to actuate a firing member through a staple firing stroke. The control circuit is coupled to the motor, wherein the control circuit comprises a motor controller configured to control the motor, and wherein, during the staple firing stroke, the control circuit is configured to actuate the firing member through the staple firing stroke, monitor a parameter of the motor system during the staple firing stroke, identify when the firing member is within an active adjustment portion of the staple firing stroke; and automatically adjust, at a frequency, tuning parameters of the motor controller with based on the monitored parameter of the motor system during the active adjustment portion of the staple firing stroke.

Abstract: Methods, devices, and systems for controlling a tissue-treatment motion by a surgical instrument are disclosed.

Abstract: A surgical instrument system comprising a motor system and a control circuit is disclosed. The motor system comprises a motor and a drive train movable by the motor to actuate a firing member through a staple firing stroke. The control circuit is coupled to the motor, wherein, during the staple firing stroke, the control circuit is configured to perform a first sensory action to determine if a speed of the motor can be increased to a first target speed, monitor a result of the first sensory action, adjust a parameter of a subsequent sensory action based on the monitored result of the first sensory action, and perform the subsequent sensory action with the adjusted parameter.

Abstract: A surgical instrument system comprising a drive train and a control circuit is disclosed. The drive train comprises a motor and a shaft actuatable by the motor to actuate a function of an end effector. The control circuit is coupled to the motor, wherein the control circuit is configured to determine a relative excess capacity of the drive train, compare the relative excess capacity to a predetermined shifting threshold, and increase the speed of the motor based on the relative excess capacity exceeding the predetermined shifting threshold.

Abstract: A surgical stapling system includes a motor, a gear reducer assembly, a drive train, and a motor controller. A method of controlling the motor includes applying a first signal to the motor, receiving drive train operational data, comparing the drive train data to baseline data, and applying a signal having a different shape than the first signal to the motor. A method of characterizing the motor includes transmitting a perturbation signal, receiving motor function parameters, determining stapler system characteristics, and adjusting a controller function. A method of controlling a stepper motor includes applying a signal to the stepper motor, receiving stepper motor operational data, comparing the data to baseline data, and adjusting the signal. Another method of controlling the motor includes receiving motor rotational data, receiving gear rotation data, calculating a mechanical transfer function, determining non-idealities of the stapling system, and modifying a control signal based on the non-idealities.

Abstract: A surgical instrument includes a body, a shaft, a motor, a firing assembly, an end effector, and a control circuit. The motor is activatable to actuate the firing assembly through a firing stroke to staple and sever tissue with the end effector. The control circuit is configured to monitor one or more use metrics of the surgical instrument. Responsive to at least one of the one or more use metrics exceeding a predetermined threshold, the control circuit is further configured to initiate at least one of providing a notification to a user or disabling the firing assembly.

Abstract: A forming system includes a first die assembly having a first die surface, a second die assembly having a second die surface; a movable die block having a third die surface; and a cooling system. The first die surface, the second die surface and the third die surface are configured to cooperate to form a die cavity therebetween so as to receive a work piece therein. A relative movement between the first die assembly and the second die assembly along a first axis moves the die cavity between an open position and a closed position. The die block is movable relative to the first die assembly in a direction transverse to the first axis and applies a force to the work piece that is predominantly transverse to forces applied to the work piece by the first die assembly and the second die assembly.

Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Abstract: This invention relates to the use of pyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of pyrimidinones in the treatment of cancer.

Abstract: This invention relates to the use of spirocyclic piperidine derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.

Abstract: This invention relates to the use of triazolone and triazolethione derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones and triazolethiones in the treatment of cancer.

Abstract: A method of forming a shaped product from an initial blank comprises subjecting the initial blank to a hot forming and press hardening operation to form the shaped product with substantially a uniform first tensile strength. Subsequently, the shaped product is at least partially immersed into a fluidized bed that is maintained within a known range of operating temperatures. While the shaped product is immersed into the fluidized bed, a first region of the shaped product is heated selectively to above a known temperature. The first region is then cooled, such that the first region attains a second tensile strength that is substantially less than the first tensile strength.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.